Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 123.26B, Vertex Pharmaceuticals(VRTX) trades at $485.65. The stock has a price-to-earnings ratio of 28.81.
On 2026-07-18, Vertex Pharmaceuticals(VRTX) stock traded between a low of $481.98 and a high of $496.69. Shares are currently priced at $485.65, which is +0.8% above the low and -2.2% below the high.
Vertex Pharmaceuticals(VRTX) shares are trading with a volume of 1.51M, against a daily average of 1.6M.
In the last year, Vertex Pharmaceuticals(VRTX) shares hit a 52-week high of $533.67 and a 52-week low of $362.50.
In the last year, Vertex Pharmaceuticals(VRTX) shares hit a 52-week high of $533.67 and a 52-week low of $362.50.
VRTX News
Earlier in July 2026, U.S. regulators expanded approval of Vertex’s gene-editing therapy Casgevy to children as young as 2 with sickle cell disease or transfusi...
Vertex Pharmaceuticals Inc. (VRTX) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the i...
Vertex Pharmaceuticals (NasdaqGS:VRTX) agreed to acquire Crinetics Pharmaceuticals in a US$10b all cash transaction. The deal brings atumelnant, an advanced cl...
Analyst ratings
77%
of 31 ratingsMore VRTX News
Key Points Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of Vertex's future. Management says it was "floored...
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $387.15, moving -1.08% from the previous trading session. This change lagged the S&P 500's d...
UBS raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $585 from $545 and keeps a Buy rating on the shares. TipRanks has entered a new arena in...
Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Vertex Pharmaceuticals and increased the price target to $600.00 from $598.00....
Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transacti...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.